Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 3:2018:18-0048.
doi: 10.1530/EDM-18-0048. eCollection 2018.

Gastric neuroendocrine neoplasm with late liver metastasis

Affiliations

Gastric neuroendocrine neoplasm with late liver metastasis

Bernardo Marques et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

Gastric neuroendocrine neoplasms (GNENs) are classified into three types according to their aetiology. We present a clinical case of a female patient of 66 years and a well-differentiated (grade 2), type 3 GNEN with late liver metastasis (LM). The patient underwent surgical excision of a gastric lesion at 50 years of age, without any type of follow-up. Sixteen years later, she was found to have a neuroendocrine tumour (NET) metastatic to the liver. The histological review of the gastric lesion previously removed confirmed that it was a NET measuring 8 mm, pT1NxMx (Ki67 = 4%). 68Ga-DOTANOC PET/CT reported two LM and a possible pancreatic tumour/gastric adenopathy. Biopsies of the lesion were repeatedly inconclusive. She had a high chromogranin A, normal gastrin levels and negative anti-parietal cell and intrinsic factor antibodies, which is suggestive of type 3 GNEN. She underwent total gastrectomy and liver segmentectomies (segment IV and VII) with proven metastasis in two perigastric lymph nodes and both with hepatic lesions (Ki67 = 5%), yet no evidence of local recurrence. A 68Ga-DOTANOC PET/CT was performed 3 months after surgery, showing no tumour lesions and normalisation of CgA. Two years after surgery, the patient had no evidence of disease. This case illustrates a rare situation, being a type 3, well-differentiated (grade 2) GNEN, with late LM. Despite this, it was possible to perform surgery with curative intent, which is crucial in these cases, as systemic therapies have limited efficacy. We emphasise the need for extended follow-up in these patients.

Learning points: GNENs have a very heterogeneous biological behaviour.Clinical distinction between the three types of GNEN is essential to plan the correct management strategy.LMs are rare and more common in type 3 and grade 3 GNEN.Adequate follow-up is crucial for detection of disease recurrence.Curative intent surgery is the optimal therapy for patients with limited and resectable LM, especially in well-differentiated tumours (grade 1 and 2).

PubMed Disclaimer

Figures

Figure 1
Figure 1
68Ga-DOTANOC PET/CT reported two liver metastases and a lesion between the stomach and pancreas, which was thought to be a possible pancreatic tumour/gastric adenopathy.
Figure 2
Figure 2
68Ga-DOTANOC PET/CT performed 3 months after surgery showed no tumour lesions.

References

    1. Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, et al ENETS Consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016. 103 119–124. (10.1159/000443168) - DOI - PubMed
    1. Lepage C, Bouvier AM, Faivre J. Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours. European Journal of Endocrinology 2013. 168 77–83. (10.1530/EJE-12-0418) - DOI - PubMed
    1. Li T-T, Qian Z-R, Wan J, Qi X-K, Wu B-Y. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World Journal of Gastroenterology 2014. 20 118–125. (10.3748/wjg.v20.i1.118) - DOI - PMC - PubMed
    1. Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Review of Endocrinology and Metabolism 2016. 11 311–327. (10.1080/17446651.2016.1199952) - DOI - PubMed
    1. Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases: treatment of neuroendocrine liver metastases. Cancer 2015. 121 1172–1186. (10.1002/cncr.28760) - DOI - PubMed